261 related articles for article (PubMed ID: 25876105)
1. Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence.
Wagner J; Damaschke N; Yang B; Truong M; Guenther C; McCormick J; Huang W; Jarrard D
PLoS One; 2015; 10(4):e0124366. PubMed ID: 25876105
[TBL] [Abstract][Full Text] [Related]
2. Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.
Blute ML; Damaschke N; Wagner J; Yang B; Gleave M; Fazli L; Shi F; Abel EJ; Downs TM; Huang W; Jarrard DF
PLoS One; 2017; 12(2):e0172048. PubMed ID: 28234906
[TBL] [Abstract][Full Text] [Related]
3. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia.
Choi J; Shendrik I; Peacocke M; Peehl D; Buttyan R; Ikeguchi EF; Katz AE; Benson MC
Urology; 2000 Jul; 56(1):160-6. PubMed ID: 10869659
[TBL] [Abstract][Full Text] [Related]
4. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase.
Lee BY; Han JA; Im JS; Morrone A; Johung K; Goodwin EC; Kleijer WJ; DiMaio D; Hwang ES
Aging Cell; 2006 Apr; 5(2):187-95. PubMed ID: 16626397
[TBL] [Abstract][Full Text] [Related]
5. Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFβ1 signaling pathway modulation.
Teixeira AL; Gomes M; Nogueira A; Azevedo AS; Assis J; Dias F; Santos JI; Lobo F; Morais A; Maurício J; Medeiros R
PLoS One; 2013; 8(8):e72419. PubMed ID: 23951322
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
8. HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy.
Slezak J; Truong M; Huang W; Jarrard D
BMC Cancer; 2013 Mar; 13():148. PubMed ID: 23522301
[TBL] [Abstract][Full Text] [Related]
9. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material.
Peng Z; Andersson K; Lindholm J; Dethlefsen O; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
PLoS One; 2016; 11(1):e0145545. PubMed ID: 26731648
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta cytokines increase senescence-associated beta-galactosidase activity in human prostate basal cells by supporting differentiation processes, but not cellular senescence.
Untergasser G; Gander R; Rumpold H; Heinrich E; Plas E; Berger P
Exp Gerontol; 2003 Oct; 38(10):1179-88. PubMed ID: 14580871
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.
Ewald JA; Desotelle JA; Church DR; Yang B; Huang W; Laurila TA; Jarrard DF
Prostate; 2013 Mar; 73(4):337-45. PubMed ID: 22911222
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
14. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER.
Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
Georgian Med News; 2015 Dec; (249):7-14. PubMed ID: 26719543
[TBL] [Abstract][Full Text] [Related]
15. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells.
Schwarze SR; Shi Y; Fu VX; Watson PA; Jarrard DF
Oncogene; 2001 Dec; 20(57):8184-92. PubMed ID: 11781834
[TBL] [Abstract][Full Text] [Related]
16. Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer.
Saoud R; Heidar NA; Cimadamore A; Paner GP
Cells; 2020 Sep; 9(9):. PubMed ID: 32957584
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
18. Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients.
Avgeris M; Stravodimos K; Scorilas A
Biol Chem; 2014 Sep; 395(9):1095-104. PubMed ID: 25153390
[TBL] [Abstract][Full Text] [Related]
19. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
